rawfin.tv
Amgen CEO Discusses AI's Impact on Biotechnology
TechnologytechAI Generated

Amgen CEO Discusses AI's Impact on Biotechnology

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Amgen Chairman and CEO Bob Bradway shared his insights on the transformative potential of artificial intelligence within the biotechnology sector. He highlighted how AI is poised to reshape future innovations and operational efficiencies in the industry.

AmgenAIbiotechnologyinnovation

Related Articles

Amazon's AI Business Reaches $25 Billion Run Rate

Amazon's AI Business Reaches $25 Billion Run Rate

tech
OpenAI Nears $30 Billion Funding Round at $1.25 Trillion Valuation

OpenAI Nears $30 Billion Funding Round at $1.25 Trillion Valuation

tech
Anthropic S-1 Filing Reveals $80.7 Billion First-Half Loss Ahead of IPO

Anthropic S-1 Filing Reveals $80.7 Billion First-Half Loss Ahead of IPO

tech
Apple Partners with Meta to Run 816-Billion AI Model Locally

Apple Partners with Meta to Run 816-Billion AI Model Locally

tech